

Chan Yoon Cheah

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1431371/chan-yoon-cheah-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

2,193
citations

21
h-index

45
g-index

113
ext. papers

2,852
ext. citations

3.9
avg, IF

5.09
L-index

#	Paper	IF	Citations
106	Marginal zone lymphoma: present status and future perspectives.. <i>Haematologica</i> , 2022 , 107, 35-43	6.6	4
105	Timing of high dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1,384 patients.. <i>Blood</i> , 2022 ,	2.2	3
104	New Directions for Mantle Cell Lymphoma in 2022.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 42, 1-15	7.1	
103	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. <i>Blood</i> , 2021 , 138, 181-181	2.2	3
102	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021 , 138, 381-381	2.2	2
101	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021 , 138, 3527-3527	2.2	0
100	Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study. <i>Blood</i> , 2021 , 138, 1456-1456	2.2	
99	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021 , 138, 391-391	2.2	2
98	Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients. <i>Blood</i> , 2021 , 138, 452-452	2.2	
97	The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies. <i>Blood</i> , 2021 , 138, 1549-1549	2.2	1
96	Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance. <i>HemaSphere</i> , 2021 , 5, e648	0.3	0
95	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet, The</i> , 2021 , 397, 892-901	40	81
94	The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. <i>British Journal of Haematology</i> , 2021 , 195, 15-24	4.5	3
93	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1129-1138	2.2	7
92	Umbralisib, a Dual PI3K/CK1 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1609-1618	2.2	36
91	Simultaneous intraocular and cutaneous extranodal NK/T-cell lymphoma refractory to multiple therapies including pembrolizumab. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e04194	0.7	0
90	Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. <i>Blood Advances</i> , 2021 , 5, 2426-2437	7.8	4

89	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. <i>British Journal of Haematology</i> , 2021 , 192, 1049-1053	4.5	13
88	Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	8
87	Integrated safety analysis of umbralisib, a dual PI3K/CK1 inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021 , 5, 5332-5343	7.8	2
86	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020 , 50, 667-679	1.6	25
85	Mantle cell lymphoma - where precision medicine based on response-adapted treatment strategies could show its full worth. <i>British Journal of Haematology</i> , 2020 , 189, 600-602	4.5	
84	Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. <i>Blood</i> , 2020 , 136, 36-38	2.2	
83	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020 , 136, 46-49	2.2	
82	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020 , 189, 661-671	4.5	8
81	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020 , 136, 8-10	2.2	5
80	Umbralisib, the Once Daily Dual Inhibitor of PI3K and Casein Kinase-1 Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial. <i>Blood</i> , 2020 , 136, 34-35	2.2	5
79	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020 , 136, 35-37	2.2	11
78	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. <i>Blood</i> , 2020 , 136, 45-46	2.2	13
77	Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. <i>Blood</i> , 2020 , 136, 42-44	2.2	27
76	Detection of Del(17p) in Hematological Malignancies By Imaging Flow Cytometry. <i>Blood</i> , 2020 , 136, 9-10	2.2	3
75	An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. <i>Cancer Medicine</i> , 2020 , 9, 663-670	4.8	9
74	Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3412-3416	1.9	0
73	Event free survival at 12 months (EFS12) in stage 1 DLBCL - a reassuring milestone?. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2542-2543	1.9	
72	Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2019 , 152, 818-827	1.9	2

71	Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy. <i>European Journal of Cancer</i> , 2019 , 115, 84-87	7.5	2
70	Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations. <i>British Journal of Haematology</i> , 2019 , 187, 73-81	4.5	10
69	Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. <i>British Journal of Haematology</i> , 2019 , 186, 409-419	4.5	3
68	Management of patients with follicular lymphoma treated first line with obinutuzumab. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019 , 15 Suppl 3, 3-11	1.9	
67	Designing optimal prognostic models for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1848-1850	1.9	
66	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. <i>Hematological Oncology</i> , 2019 , 37, 253-260	1.3	2
65	Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. <i>Internal Medicine Journal</i> , 2019 , 49, 1070-1080	1.6	5
64	Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. <i>British Journal of Haematology</i> , 2019 , 185, 334-338	4.5	5
63	Refractory ∇ Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e564-e567	2	3
62	Author reply. <i>Internal Medicine Journal</i> , 2019 , 49, 1338-1339	1.6	
61	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019 , 134, 6-6	2.2	105
60	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk. <i>Blood</i> , 2019 , 134, 4728-4728	2.2	2
59	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. <i>Blood</i> , 2019 , 134, 170-170	2.2	12
58	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019 , 3, 1356-1367	7.8	9
57	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019 , 3, 2013-2021	7.8	19
56	Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. <i>Blood Advances</i> , 2019 , 3, 2804-2811	7.8	11
55	Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma. <i>Internal Medicine Journal</i> , 2019 , 49, 422-433	1.6	5
54	Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?. <i>Annals of Hematology</i> , 2019 , 98, 1169-1176	3	6

53	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018 , 93, 57-68	7.5	37
52	Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. <i>Leukemia and Lymphoma</i> , 2018 , 59, 775-777	1.9	
51	Impact of Induction Chemotherapy and Primary CNS Prophylaxis on Outcomes in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements (HGBL-DH/TH) or HGBL-NOS: An International Multi-Center Retrospective Analysis. <i>Blood</i> , 2018 , 132, 4224-4224	2.2	
50	Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients. <i>Blood</i> , 2018 , 132, 452-452	2.2	
49	Novel agents for relapsed and refractory follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018 , 31, 41-48	4.2	16
48	Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. <i>Oncotarget</i> , 2018 , 9, 28897-28902	3.3	15
47	When to treat patients with relapsed follicular lymphoma. <i>Expert Review of Hematology</i> , 2017 , 10, 187-192	1.8	7
46	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , 2017 , 75, 195-203	7.5	35
45	Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2017 , 130, 472-477	2.2	45
44	How I treat patients with aggressive lymphoma at high risk of CNS relapse. <i>Blood</i> , 2017 , 130, 867-874	2.2	12
43	Three different hematologists, three different answers: how should we treat concurrent systemic and central nervous system lymphoma?. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1-3	1.9	
42	High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 991-994	4.5	6
41	The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	0
40	Primary Testicular Lymphoma 2017 , 129-141		1
39	Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1044-53	1.9	5
38	Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2016 , 137, 1659-1669	2.7	225
37	Synchronous biphenotypic Richter syndrome with Epstein-Barr virus-positive nodal classical Hodgkin lymphoma and bone marrow diffuse large B-cell lymphoma. <i>Histopathology</i> , 2016 , 69, 707-10	7.3	2
36	Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1974-6	1.9	3

35	Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1256-69	2.2	186
34	Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. <i>Neuro-Oncology</i> , 2016 , 18, 575-81	1	15
33	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1874-1874	2.2	2
32	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016 , 91, 894-9	7.1	11
31	Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2612-8	1.9	1
30	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016 , 101, 531-40	6.6	52
29	Idelalisib in the management of lymphoma. <i>Blood</i> , 2016 , 128, 331-6	2.2	97
28	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. <i>British Journal of Haematology</i> , 2016 , 175, 876-883	4.5	18
27	Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. <i>British Journal of Haematology</i> , 2016 , 175, 531-533	4.5	7
26	Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016 , 172, 80-8	4.5	67
25	Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?. <i>Current Oncology Reports</i> , 2015 , 17, 25	6.3	16
24	Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. <i>Lancet Haematology</i> , 2015 , 2, e166-74	14.6	29
23	A clinician's guide to double hit lymphomas. <i>British Journal of Haematology</i> , 2015 , 168, 784-95	4.5	52
22	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. <i>Current Opinion in Oncology</i> , 2015 , 27, 384-91	4.2	15
21	Novel treatments for T-cell lymphoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e468-78	7.1	1
20	Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. <i>Annals of Hematology</i> , 2015 , 94, 1605-7	3	7
19	Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. <i>Blood</i> , 2015 , 125, 3357-9	2.2	78
18	Diffuse large B-cell lymphoma with microsatellite instability developing in the setting of Muir-Torre variant hereditary non-polyposis colon cancer. <i>Journal of Clinical Pathology</i> , 2015 , 68, 755-7	3.9	4

17	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. <i>Blood</i> , 2014 , 123, 3574-7	2.2	91
16	IgG4-related disease with cutaneous manifestations treated with rituximab: case report and literature review. <i>Australasian Journal of Dermatology</i> , 2014 , 55, 132-6	1.3	17
15	Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. <i>Journal of Clinical Oncology</i> , 2014 , 32, 114-20	2.2	269
14	Primary testicular lymphoma. <i>Blood</i> , 2014 , 123, 486-93	2.2	111
13	Primary breast lymphoma. <i>Cancer Treatment Reviews</i> , 2014 , 40, 900-8	14.4	71
12	Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?. <i>Leukemia and Lymphoma</i> , 2014 , 55, 471-3	1.9	
11	Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma. <i>International Journal of Hematologic Oncology</i> , 2014 , 3, 189-201	1	1
10	Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1859-61	1.9	1
9	Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency. <i>Acta Haematologica</i> , 2013 , 130, 254-9	2.7	21
8	Rituximab for the treatment of follicular lymphoma. <i>Future Oncology</i> , 2013 , 9, 1283-98	3.6	3
7	All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab. <i>European Journal of Haematology</i> , 2013 , 91, 189-90	3.8	
6	Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013 , 122, 4353-4353	2.2	4
5	11q23 rearrangement and duplication of MLLT1-MLL gene fusion in therapy-related acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2066-8	1.9	5
4	Fibrinogen Melbourne: a novel congenital hypodysfibrinogenemia caused by B26Cys-Phe in the fibrinogen α chain, presenting as massive splanchnic venous thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2012 , 23, 563-5	1	11
3	Fluoroquinolone-induced immune thrombocytopenia: a report and review. <i>Internal Medicine Journal</i> , 2009 , 39, 619-23	1.6	20
2	Comment on "Drug-induced thrombocytopenia: an updated systematic review". <i>Drug Safety</i> , 2009 , 32, 707; author reply 708	5.1	4
1	Mirtazapine associated with profound hyponatremia: two case reports. <i>American Journal of Geriatric Pharmacotherapy</i> , 2008 , 6, 91-5		9